Drug Channels delivers timely analysis and provocative opinions on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 100,000 subscribers and followers. Learn more...
Today's guest post comes from Geoff Chaiken, CEO at BlinkRx.
Geoff examines the different roles of telemedicine, consumer rebates through cash discount cards, and cash-pay pharmacies in direct-to-patient (DTP) prescription access. He argues that while each can improve access, none fully addresses the challenges of prescription fulfillment and adherence. He makes the case for a more comprehensive approach that integrates affordability, insurance coverage, and pharmacy fulfillment throughout the patient journey.
To learn more about BlinkRx's RxOS prescription operating system, visit BlinkRx.
This split is a belated acknowledgement that the synergies between CVS Pharmacy and Caremark were overblown from the start. As I argue below, CVS Pharmacy will have greater freedom to make the hard choices—and also find new friends. Regulatory and legislative risks are real, but I view this primarily as a strategic and financial decision.
I’ll have a lot more to say about the future of vertical integration during the Drug Channels Outlook 2027, which will be my final DCI webinar.
Don’t miss this final opportunity to hear Adam’s unfiltered, data-driven outlook on the forces shaping the drug channel—and what they mean for your organization in 2027 and beyond.
For more than 20 years, Adam has brought you an unfiltered, data-driven look at the most important trends, market forces, and policy developments in the drug channel. In his final webinar before retiring from DCI, he’ll examine where the industry is heading—and what his two decades of tracking its evolution reveal about what comes next. Adam will share his unfiltered outlook on key issues where he has been a pioneering voice, including:
Consolidation, vertical integration, and industry power
The 340B Drug Pricing Program and the 340Boom
Accumulators, maximizers, and shady alternative funding programs
The Gross-to-Net Bubble and SpongeBob SquarePants
The Net Pricing Drug Channel (#NPDC)
Antonio, Tyler, and Bryce will also explore:
PBM reform: Real change or more of the same?
What new CMS and DOL rules mean for plan sponsors and the PBM business
The Inflation Reduction Act’s impact on Medicare Part B and Part D
The future of pharmacy profits and reimbursement
Patient-paid prescriptions and direct-to-patient disruption
The November elections’ impact on the drug channel
What’s ahead for most favored nation pricing
Biosimilars and the buy-and-bill market
Wholesalers’ next growth opportunities
As always, the speakers will clearly distinguish their opinions and interpretations from the objective facts and data.
This 90-minute video webinar will include a dedicated Q&A session, during which attendees can unmute and engage directly with Adam and the other speakers.
Can’t attend the live event? After each event, every registrant will receive an email with information on how to view a replay of the video recording. Every registrant will also be able to download a PDF of the full slide deck.
Register for $420 per viewing device. Within one business day of registering, you'll receive a unique Zoom access link and details for adding the event to your calendar.
Special Team Discounts
We offer substantial savings when an organization purchases multiple registrations. An unlimited number of attendees can watch together at a single physical location using one registered device.
Important Reminder: Each viewing device must have its own registration. Attendees may not record the webinar or broadcast its audio or video to other devices or locations.
Register now. All discounts will be automatically calculated based on the number of registrations you enter in your cart.
Purchasing access for multiple devices or locations? We’ll contact you for your participant list. Alternatively, download this spreadsheet and email your registrants’ information to dcisupport@hmpglobal.com.
Watch and listen using any modern browser on a computer, tablet, or mobile device. (No telephone access.)
Each registrant will receive an email with a link to watch the event. This link is unique to the registrant and is valid for one registered viewing device.
Every registrant will also receive a link to download the complete slide deck.
This event is part of The Drug Channels 2026 Video Webinar Series. If you already purchased access to the series, you should already have received an email from Zoom with a link to access the December 11, 2026, event.
Organizations that purchased corporate access to The Drug Channels 2026 Video Webinar Series will receive a custom, branded signup link so employees can easily register. We will automatically refund payments from anyone at a company with corporate access who purchases a single registration using their corporate email address.
Each registration for a DCI webinar is valid for a single device at a single physical location. Attendees are not permitted to record, stream, share, or project a DCI webinar to other sites or locations. Purchasers who violate this limitation by recording, streaming, sharing, or projecting a DCI webinar to other sites, devices, or locations will be liable for the full cost of all locations that viewed the webinar. DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars.
Except for the corporate-access refunds described above, we are unable to offer refunds.
Today's guest post comes from Danny Sigurdson, Founder and CEO at Courier Health.
Danny examines how biopharma companies are approaching patient services, partner changes, and artificial intelligence in 2027. He argues that connected data and purpose-built technology can improve operational efficiency, accelerate access to therapy, and enhance the patient experience.
.png)